[HTML][HTML] Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR …
Q Zhou, Y Cheng, JJ Yang, MF Zhao, L Zhang… - Annals of oncology, 2014 - Elsevier
Background CTONG0806 assessed the efficacy of pemetrexed versus gefitinib as second-
line treatment in advanced nonsquamous nonsmall-cell lung cancer (NSCLC) harboring …
line treatment in advanced nonsquamous nonsmall-cell lung cancer (NSCLC) harboring …
[HTML][HTML] First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or …
JCH Yang, JH Kang, T Mok, MJ Ahn… - European Journal of …, 2014 - Elsevier
Abstract Background In the Iressa Pan-ASia Study (IPASS), gefitinib claimed improved
progression-free survival (PFS) versus carboplatin-paclitaxel in clinically selected lung …
progression-free survival (PFS) versus carboplatin-paclitaxel in clinically selected lung …
[HTML][HTML] First-line Pemetrexed plus cisplatin followed by Gefitinib maintenance therapy versus Gefitinib monotherapy in east Asian never-smoker patients with locally …
JCH Yang, V Srimuninnimit, MJ Ahn, CC Lin… - Journal of Thoracic …, 2016 - Elsevier
Introduction The primary analysis of this open-label, randomized, multicenter phase 3 study
revealed no significant difference in progression-free survival between pemetrexed plus …
revealed no significant difference in progression-free survival between pemetrexed plus …
Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with …
A Nakamura, A Inoue, S Morita, Y Hosomi, T Kato… - 2018 - ascopubs.org
9005 Background: Although EGFR-TKI alone has been a standard first-line treatment for pts
with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed …
with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed …
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive …
N Yoshimura, S Kudoh, S Mitsuoka, N Yoshimoto… - Lung cancer, 2015 - Elsevier
Purpose Patients with advanced non-small cell lung cancer (NSCLC) harboring a sensitive
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non–small-cell lung cancer with …
Y Cheng, H Murakami, PC Yang, J He… - Journal of Clinical …, 2016 - ascopubs.org
Purpose To determine whether the addition of pemetrexed to gefitinib (P+ G) provides
clinical benefit, compared with gefitinib monotherapy, in patients with advanced …
clinical benefit, compared with gefitinib monotherapy, in patients with advanced …
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
Purpose Gefitinib is an effective first-line chemotherapy for advanced non-small cell lung
cancer (NSCLC) patients harboring sensitive EGFR mutations. However, whether second …
cancer (NSCLC) patients harboring sensitive EGFR mutations. However, whether second …
[HTML][HTML] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer …
A Inoue, K Kobayashi, M Maemondo, S Sugawara… - Annals of oncology, 2013 - Elsevier
Background NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell …
9001 Background: Standard first-line therapy for EGFR mutant advanced non-small cell lung
cancer (NSCLC) is an EGFR-directed oral TKI. We evaluated whether adding pemetrexed …
cancer (NSCLC) is an EGFR-directed oral TKI. We evaluated whether adding pemetrexed …
[HTML][HTML] Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with …
S Sugawara, S Oizumi, K Minato, T Harada, A Inoue… - Annals of oncology, 2015 - Elsevier
ABSTRACT EGFR-TKI therapy produces a dramatic clinical response in patients with
NSCLC harboring EGFR mutation. However, clinical outcomes should be improved further …
NSCLC harboring EGFR mutation. However, clinical outcomes should be improved further …